Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Rating Lowered by Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by research analysts at Guggenheim from a “buy” rating to a “hold” rating in a report released on Thursday, Marketbeat reports.

CNTA has been the topic of several other research reports. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $40.00.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $39.69 on Thursday. The stock has a market cap of $6.13 billion, a price-to-earnings ratio of -27.00 and a beta of 1.25. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average price is $27.21 and its two-hundred day moving average price is $25.57. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity

In related news, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 over the last three months. Insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. grew its position in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares in the last quarter. Wells Fargo & Company MN grew its position in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after purchasing an additional 1,008 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

More Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Unusually large purchase of call options — shows bullish speculative interest and potential short-term demand from options traders, which can support the equity even as analysts trim ratings. Investors Purchase High Volume of Centessa Pharmaceuticals Call Options
• Neutral Sentiment: High overall options activity flagged — elevated options volume was reported, but the report does not fully clarify position directions (mix of puts/calls), so the net impact is uncertain. Centessa Pharmaceuticals Target of Unusually High Options Trading
• Negative Sentiment: Guggenheim downgraded CNTA from “buy” to “hold” — a notable sell-side cut from a sizable shop that reduces buy-side conviction and can pressure the stock. Guggenheim downgrades Centessa Pharmaceuticals plc – Depositary Receipt (CNTA)
• Negative Sentiment: Leerink Partners lowered its rating to “hold” — another research downgrade that contributes to negative analyst sentiment. Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to “Hold” at Leerink Partners
• Negative Sentiment: Stephens cut CNTA to “hold” — adds to a cluster of downgrades from independent research shops. Centessa Pharmaceuticals (NASDAQ:CNTA) Cut to Hold at Stephens
• Negative Sentiment: Multiple other firms (Wolfe Research, Needham, B. Riley and Lifesci Capital) trimmed ratings or moved from “strong-buy” to “hold” — broad-based analyst downgrades increase selling pressure and reduce near-term upside expectations. Wolfe Research Downgrades Centessa Pharmaceuticals to Hold Needham & Company LLC Lowers Rating B. Riley / Lifesci coverage notes

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.